Carregant...
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia
BACKGROUND: Benign prostatic hyperplasia (BPH) refers to non‐malignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha‐blockers (ABs) and 5‐alpha reductase inhibitors (5‐ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase in...
Guardat en:
| Publicat a: | Cochrane Database Syst Rev |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Ltd
2018
|
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6517182/ https://ncbi.nlm.nih.gov/pubmed/30480763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010060.pub2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|